Sign in
Taking peoplePhase 3

Tests KarXT for psychosis linked to Alzheimer's disease

Tests KarXT against placebo in people with Alzheimer's-related psychosis to prevent relapse.

Key facts

Who runs it
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Where
Junggu, Pusan, and Seoul, South KoreaSee the 3 sitesAlso in 12 other countries, 123 sites
Registry title
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Status
Recruiting
Phase
Phase 3
People taking part
410 people, planned
Started
23 Aug 2022
Planned end
5 Oct 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • KarXT
  • Placebo
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 55 to 90 with Alzheimer's Disease who have had delusions or hallucinations (psychosis) for at least 2 months. It tests KarXT against placebo.

Age
55 to 90 years
Sex
All sexes can join.
Disease stage
Possible or probable Alzheimer's Disease with psychosis for at least 2 months. Moderate or worse severity (CGI-S score of 4 or more). Moderate to severe delusions or hallucinations. MMSE score of 6 to 24.
Earlier treatment
If taking a cholinesterase inhibitor or memantine, the dose must be stable for 6 weeks before screening. People must not have had KarXT before. Other psychoactive medicines must be stopped, with some exceptions.

Main reasons for not taking part

  • Psychosis mainly caused by something other than Alzheimer's Disease
  • Bipolar disorder, schizophrenia or schizoaffective disorder
  • Serious heart, liver, kidney or other medical conditions
  • Stroke within 12 months before screening
  • Known sensitivity to trospium or earlier KarXT use

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Is aged 55 to 90 years, inclusive, at Screening
  • Can understand the nature of the study and protocol requirements and provide a signed informed consent form before any study assessments are performed. If the subject is deemed not competent to provide consent, the following requirements for consent must be met; The subject's legally acceptable representative must provide informed consent; ii) The subject must provide assent or similar where permitted per local law/regulation and as approved by the IRB/IEC
  • Meets clinical criteria for possible or probable Alzheimer's Disease
  • Has a Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome. If not available, a non-contrast brain MRI or non-contrast head CT must be done during screening
  • Living at the same location for a minimum of 4 weeks before Screening, with the intention of living at the same location throughout the study
  • Capable of self-locomotion (alone or with the aid of an assistive device) and have an identified caregiver or study partner who, in the investigator's judgment, has frequent and sufficient contact with the participant (ie, ≥ approximately 7 hours per week) on a regular basis to reliably provide accurate information regarding the participant's cognitive, behavioral, and functional status, and is willing to:; Attend all visits and report on participant's status. ii) Oversee participant compliance with medication and study procedures; iii) Participate in the study assessments and provide informed consent to participate in the study
  • History of psychotic symptoms (meeting International Psychogeriatric Association [IPA] criteria) for at least 2 months prior to Screening
  • Clinical Global Impressions-Severity (CGI-S) scale with a score ≥4 (moderate) at Screening and Baseline. CGI-S requires the assessor to consider aspects of the psychosis prior to providing a global assessment of severity. These aspects include hallucinations and delusions
  • Subjects are required to meet at least one of the following criteria at Screening and Baseline:; Moderate to severe delusions, defined as Neuropsychiatric Inventory-Clinician (NPI-C): Delusions domain score of ≥2 on two of the eight items OR; ii) Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on two of the seven items
  • Mini-Mental State Examination (MMSE) score of 6 to 24, inclusive, at Screening
  • If the subject is taking a cholinesterase inhibitor and/or memantine, they must have been on a stable dose for 6 weeks prior to Screening and be willing to maintain a stable dose for the duration of the study
  • Participant is willing and able to attend the study visit for the study duration, follow instructions, and comply with the protocol requirements
  • BMI must be within 16 to 40 kg/m2 and participants with a BMI of 16 to <18 kg/m2 must have a body weight ≥40 kg
  • A female (as assigned at birth) is eligible to participate if she is not pregnant or breastfeeding. Individual of childbearing potential (IOCBP) must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of IMP

Who cannot take part

  • History of major depressive episode with psychotic features during the 12 months prior to Screening
  • History of ischemic stroke within 12 months prior to Screening or any evidence of hemorrhagic stroke
  • Myocardial infarction within the 6 months prior to Screening
  • Currently receiving monoamine oxidase inhibitors, anticonvulsants (e.g., lamotrigine, divalproex), mood stabilizers (eg, lithium) tricyclic antidepressants (e.g., imipramine, desipramine), or any other psychoactive medications except for as-needed anxiolytics (e.g., lorazepam) and unable to complete the washout:; Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening may be permitted; ii) Mirtazapine or trazodone may be used if started at least 8 weeks prior to Screening. If needed, an extension (up to two weeks) of the Screening Period may be allowed with approval of the Sponsor/Medical Monitor
  • Positive test for coronavirus (COVID-19) within 2 weeks before or at Screening; antigen or PCR local testing can be done at the discretion of the Investigator
  • Unable to taper and discontinue a concomitant medication that would preclude participation in the study
  • Prior exposure to KarXT
  • Participation in another clinical study in which the subject received an experimental or investigational drug within 3 months before Screening or has participated in more than 2 clinical studies in the past year
  • Psychotic symptoms that are primarily attributable to a condition other than the Alzheimer's Disease causing dementia
  • History of a diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
  • Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular or oncologic disease, or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results
  • History of cerebral amyloid angiopathy, epilepsy, central nervous system neoplasm, unstable thyroid function, or unexplained syncope
  • Any of the following:; New York Heart Association Class 2 congestive heart failure; ii) Grade 2 or greater angina pectoris; iii) Sustained ventricular tachycardia; iv) Ventricular fibrillation; v) Torsade de pointes; vi) Implantable cardiac defibrillator
  • Human immunodeficiency virus, cirrhosis, biliary duct abnormalities, active biliary disease, hepatobiliary carcinoma, and/or active hepatic viral infections as indicated by medical history or liver function tests results
  • History of obstructive gastrointestinal disorder, gastric retention, irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months
  • Experienced any significant adverse events due to trospium, including a known hypersensitivity to trospium
  • Significant or severe renal impairment based on a screening cutoff for Estimated Glomerular Filtration Rate (eGFR) of <50 mL/min
  • Personal or family history of symptoms of long QT syndrome as evaluated by the investigator
  • Participants with any of the following:; History of bladder stones; ii) History of recurrent urinary tract infections; iii) For male participants:; Serum prostate specific antigen (PSA) > 10 ng/mL at Screening; An IPSS of 5 (almost always) on items 1, 3, 5, or 6; A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9
  • Clinically significant abnormal finding on the physical examination, electrocardiogram, or clinical laboratory results at Screening
  • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the investigator
  • Risk of suicidal behavior during the study as determined by clinical assessment and/ or C-SSRS
  • Urine toxicology screen is positive substances other than cannabis or benzodiazepines (both cannabis and short-or medium-acting benzodiazepines are allowed in limited quantities during the study) unless approval has been given by the Medical Monitor
  • If, in the opinion of the Investigator and/or Sponsor/Medical Monitor, subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator and/or Sponsor/ Medical Monitor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements
  • Other protocol-defined Inclusion/Exclusion criteria apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 90 years old?

Where in South Korea

Also in 12 other countries, 123 sites

  • Local Institution - 1-14IVVWPLJunggu, South KoreaContact: Site 1-14IVVWPLNot yet recruiting
  • Local Institution - 1-14IG4A3IPusan, South KoreaContact: Site 1-14IG4A3INot yet recruiting
  • Local Institution - 1-14IG4A1RSeoul, South KoreaContact: Site 1-14IG4A1RNot yet recruiting

About the trial

What the trial wants to find out

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.

Read full original descriptionShow less

The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason or relapse and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo.

The 2 groups in the trial

  • KarXTTreatment being tested

    Xanomeline and Trospium Chloride Capsules

  • PlaceboPlacebo, for comparison

    Placebo Capsules

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Plain-language title
Tests KarXT for psychosis linked to Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05511363, who can take part
Record updated
17 August 2026